---
title: "Ananda Pharma plans exit from AQSE as it pivots to private structure"
publisher: "Share Talk"
author: "sharetalk"
published: "2025-11-26T07:52:49+00:00"
modified: "2025-11-26T07:52:49+00:00"
date: 2025-11-26
canonical: "https://www.share-talk.com/ananda-pharma-plans-exit-from-aqse-as-it-pivots-to-private-structure/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["ANA", "Ananda Developments", "Aquis Stock Exchange Growth", "CBD", "Drug", "Great Ormond Street Hospital.", "Melissa Sturgess", "University College London", "University of Edinburgh"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/03/health-care.webp?fit=1200%2C800&quality=80&ssl=1"
format: "news"
language: "en-GB"
---

# Ananda Pharma plans exit from AQSE as it pivots to private structure

**Published:** November 26, 2025
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** ANA, Ananda Developments, Aquis Stock Exchange Growth, CBD, Drug, Great Ormond Street Hospital., Melissa Sturgess, University College London, University of Edinburgh
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/03/health-care.webp?fit=1200%2C800&quality=80&ssl=1)

---

[Ananda Pharma PLC](https://www.investegate.co.uk/announcement/rns/ananda-pharma-plc--ana/posting-of-q-a/9257308) has announced plans to [withdraw its shares](https://www.share-talk.com/ananda-pharma-to-delist-from-aqse-and-go-private-to-refocus-on-drug-development/)** from the AQSE Growth Market and re-register as a private company**, proposing to continue operations under the name **Ananda Pharma Limited**.

The UK-based biopharmaceutical group has published a detailed shareholder circular alongside a **Q&A document on its website**, designed to clarify the rationale and implications of the move. Shareholders are being asked to vote on the proposals, which are positioned as part of a strategic shift to reduce regulatory costs and improve operational focus.

Ananda says the transition will allow greater flexibility and enable more efficient allocation of capital towards its core mission: the development of **regulatory-approved cannabidiol (CBD) medicines** targeting complex chronic conditions, including **endometriosis and chemotherapy-induced pain**.

The Company has received a number of questions from shareholders about the proposals to be considered at the General Meeting. Those questions and the answers from management can be found on the company’s website here: [https://investors.anandapharma.co.uk/activity-updates/PGNgYr-questions-in-relation-to-the-companys-recent-announcement-about-its-proposed-withdrawal-from-the-aqse-growth-market](https://investors.anandapharma.co.uk/activity-updates/PGNgYr-questions-in-relation-to-the-companys-recent-announcement-about-its-proposed-withdrawal-from-the-aqse-growth-market)

The company believes operating as a private entity will better support long-term clinical progress and funding strategy, while maintaining transparency and engagement with its shareholder base.

To stay up to date with Ananda’s news please follow our social media channels:  

·              Investor Hub: [https://investors.anandapharma.co.uk/s/ea8f93](https://investors.anandapharma.co.uk/s/ea8f93)

·              Instagram: [https://www.instagram.com/anandapharmaplc/](https://www.instagram.com/anandapharmaplc/)

·              LinkedIn[:](https://www.linkedin.com/company/anadevelopments/)  [https://www.linkedin.com/company/anandapharma](https://www.linkedin.com/company/anandapharma)

·              X[:](https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA) [https://twitter.com/AnandaPlc](https://twitter.com/AnandaPlc)

---

**Original URL:** https://www.share-talk.com/ananda-pharma-plans-exit-from-aqse-as-it-pivots-to-private-structure/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*
